Skip to content

Neuroprotective Effects of Dexmedetomidine on Cerebral Ischemia-Reperfusion Injury during Endovascular Intervention for Stroke and Its Correlation with Postoperative Delirium Biomarkers.

Neuroprotective Effects of Dexmedetomidine on Cerebral Ischemia-Reperfusion Injury during Endovascular Intervention for Stroke and Its Correlation with Postoperative Delirium Biomarkers.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110474
Enrollment
Unknown
Registered
2025-10-14
Start date
2025-10-15
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium

Interventions

The dexmedetomidine group ( D group, n=126 cases).:Based on the standard anesthetic protocol, dexmedetomidine was continuously infused at a rate of 0.6 µg·kg-1·h-1 during both the induction and mainte
Placebo control group (C group,n=126 cases) :Based on the standard anesthetic protocol, a volume-matched continuous infusion of normal saline was administered intravenously during the induction and ma

Sponsors

The First Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1)Patients classified as ASA (American Society of Anesthesiologists) physical status III or below, diagnosed by neurosurgery as meeting the indications for mechanical thrombectomy and undergoing the procedure. (2)Normal preoperative coagulation and platelet function tests. (3)No use of analgesics or sedatives within 1 day before surgery. (4)No allergy to the anesthetics or contrast agents used in this study. (5)Age >= 18 years. (6)The patient or their legal guardian consents to blood sampling and signs the informed consent form.

Exclusion criteria

Exclusion criteria: (1)Patients with neurological or psychiatric disorders; (2)Patients taking medications that affect the nervous or psychiatric systems; (3)Patients with irreversible brainstem injury; (4)Patients with severe cardiac, pulmonary, cerebral, hepatic, or renal diseases; (5)Patients with allergies to the drugs or materials used in this study; (6)Patients or their legal guardians refuse to participate in the study.

Design outcomes

Primary

MeasureTime frame
The incidence of postoperative delirium;

Secondary

MeasureTime frame
The severity of postoperative delirium;tau-PT217;NSE;

Countries

China

Contacts

Public ContactJi Shi

The First Hospital of Hebei Medical University

58201470@hebmu.edu.cn+86 137 8515 0317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026